Anticipated findings from the LITESPARK-011 trial (NCT04586231) to be presented during the 2026 ASCO Genitourinary Cancers ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

SAN FRANCISCO -- Despite a growing emphasis on quality-of-life (QoL) endpoints and patient-reported outcomes in cancer trials ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.

The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

According to Tang, this independence suggests that each biomarker provides unique prognostic information, making both valuable for understanding patient outcomes. Building on these findings, the ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...